Literature DB >> 27347118

Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Bingbing Yan1, Fuqiang Yin2, Q I Wang1, Wei Zhang1, L I Li3.   

Abstract

The main obstacle to the successful treatment of ovarian cancer is the development of drug resistance to combined chemotherapy. Among all the factors associated with drug resistance, DNA methylation apparently plays a critical role. In this study, we performed an integrative analysis of the 26 DNA-methylated genes associated with drug resistance in ovarian cancer, and the genes were further evaluated by comprehensive bioinformatics analysis including gene/protein interaction, biological process enrichment and annotation. The results from the protein interaction analyses revealed that at least 20 of these 26 methylated genes are present in the protein interaction network, indicating that they interact with each other, have a correlation in function, and may participate as a whole in the regulation of ovarian cancer drug resistance. There is a direct interaction between the phosphatase and tensin homolog (PTEN) gene and at least half of the other genes, indicating that PTEN may possess core regulatory functions among these genes. Biological process enrichment and annotation demonstrated that most of these methylated genes were significantly associated with apoptosis, which is possibly an essential way for these genes to be involved in the regulation of multidrug resistance in ovarian cancer. In addition, a comprehensive analysis of clinical factors revealed that the methylation level of genes that are associated with the regulation of drug resistance in ovarian cancer was significantly correlated with the prognosis of ovarian cancer. Overall, this study preliminarily explains the potential correlation between the genes with DNA methylation and drug resistance in ovarian cancer. This finding has significance for our understanding of the regulation of resistant ovarian cancer by methylated genes, the treatment of ovarian cancer, and improvement of the prognosis of ovarian cancer.

Entities:  

Keywords:  DNA methylation; bioinformatics; drug resistance; ovarian cancer

Year:  2016        PMID: 27347118      PMCID: PMC4906569          DOI: 10.3892/ol.2016.4608

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  89 in total

1.  Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients.

Authors:  Verena Materna; Paweł Surowiak; Irina Kaplenko; Merek Spaczyński; Zhenfeng Duan; Maciej Zabel; Manfred Dietel; Hermann Lage
Journal:  Virchows Arch       Date:  2007-02       Impact factor: 4.064

2.  Silencing of the UCHL1 gene in human colorectal and ovarian cancers.

Authors:  Eriko Okochi-Takada; Kazuyuki Nakazawa; Mika Wakabayashi; Akiko Mori; Shizue Ichimura; Toshiharu Yasugi; Toshikazu Ushijima
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

Review 3.  Role of ABCG2/BCRP in biology and medicine.

Authors:  P Krishnamurthy; J D Schuetz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

4.  Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.

Authors:  Yi Chen; Marcia M Bieber; Nelson N H Teng
Journal:  Mol Carcinog       Date:  2013-02-19       Impact factor: 4.784

5.  Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.

Authors:  Linda J Nicholson; Paul R Smith; Louise Hiller; Peter W Szlosarek; Christopher Kimberley; Jalid Sehouli; Dominique Koensgen; Alexander Mustea; Peter Schmid; Tim Crook
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

6.  DNA hypomethylation and ovarian cancer biology.

Authors:  Martin Widschwendter; Guanchao Jiang; Christian Woods; Hannes M Müller; Heidi Fiegl; Georg Goebel; Christian Marth; Elisabeth Müller-Holzner; Alain G Zeimet; Peter W Laird; Melanie Ehrlich
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

7.  An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.

Authors:  Her-Young Su; Hung-Cheng Lai; Ya-Wen Lin; Yu-Ching Chou; Chin-Yu Liu; Mu-Hsien Yu
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

8.  Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.

Authors:  Hui Zhang; Shiqian Zhang; Jing Cui; Aifeng Zhang; Liang Shen; Hao Yu
Journal:  Aust N Z J Obstet Gynaecol       Date:  2008-10       Impact factor: 2.100

9.  TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.

Authors:  Ning Wang; Hui Zhang; Qin Yao; Yankui Wang; Shuzhen Dai; Xingsheng Yang
Journal:  J Exp Clin Cancer Res       Date:  2012-01-16

10.  CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.

Authors:  Varinderpal S Dhillon; Mohd Shahid; Syed Akhtar Husain
Journal:  Mol Cancer       Date:  2004-12-01       Impact factor: 27.401

View more
  8 in total

Review 1.  Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?

Authors:  Julie L Hentze; Claus K Høgdall; Estrid V Høgdall
Journal:  Mol Clin Oncol       Date:  2019-01-11

2.  UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway.

Authors:  Qiang Wang; Wei Shi
Journal:  Oncol Lett       Date:  2019-01-04       Impact factor: 2.967

3.  Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.

Authors:  Mingzi Zhang; Zhongkai Tian; Yehong Sun
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

4.  Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.

Authors:  Li-Yuan Feng; Bing-Bing Yan; Yong-Zhi Huang; Li Li
Journal:  Clin Epigenetics       Date:  2021-07-21       Impact factor: 6.551

Review 5.  Bioinformatics Accelerates the Major Tetrad: A Real Boost for the Pharmaceutical Industry.

Authors:  Tapan Behl; Ishnoor Kaur; Aayush Sehgal; Sukhbir Singh; Saurabh Bhatia; Ahmed Al-Harrasi; Gokhan Zengin; Elena Emilia Babes; Ciprian Brisc; Manuela Stoicescu; Mirela Marioara Toma; Cristian Sava; Simona Gabriela Bungau
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

6.  Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.

Authors:  Xiaolin Liu; Yintao Xu; Lu Zhang; Ting Liu; Hui Zhang
Journal:  Med Sci Monit       Date:  2018-06-17

7.  Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer.

Authors:  Bingbing Yan; Chunqiu Xiong; Feifeng Huang; Mingming Zhang; Yan Mo; Hua Bai
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

8.  Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.

Authors:  Hua Tian; Li Yan; Li Xiao-Fei; Sun Hai-Yan; Chen Juan; Kang Shan
Journal:  Clin Epigenetics       Date:  2019-10-30       Impact factor: 6.551

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.